Drug application
TALWIN NX (NALOXONE HYDROCHLORIDE, PENTAZOCINE HYDROCHLORIDE)
Drugs@FDA NDA 018733 · SANOFI AVENTIS US
Key facts
| Drug name | TALWIN NX |
|---|---|
| Active ingredients | NALOXONE HYDROCHLORIDE, PENTAZOCINE HYDROCHLORIDE |
| Application type | NDA |
| Application number | 018733 |
| Company | SANOFI AVENTIS US |
| Dosage forms | TABLET, ORAL |
| Strength | EQ 0.5MG BASE;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission class | Type 4 - New Combination |
| Latest submission status date | Dec 16, 1982 |
At a glance
- 1–9 Submissions
- 10–99 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: